How much confidence should a compounded tirzepatide ad buy you? This is GLP-1 Daily. Where does Wegovy's pill momentum lead—and what could monthly semaglutide change? First, Good Life's advertising gets a reality check. Hit follow and you won't have to come looking for the next episode.
Here's GlobeNewswire:
In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Good Life Meds, LLC discontinue the challenged express health benefit and personalization claims for its compounded Tirzepatide+ products and modify its advertising to avoid conveying unsupported implied claims about product safety, efficacy, weight loss results, and personalization.
Good Life Meds marketed its compounded Tirzepatide+ with claims about weight loss, energy, blood sugar, and preserving lean muscle. That's quite a shopping list for someone trying to choose medical care. And yesterday, BBB National Programs' advertising watchdog recommended dropping the challenged health-benefit and personalization claims. Precision matters: this is an advertising self-regulation recommendation, not an FDA ruling. Eli Lilly brought the challenge—and Lilly sells Mounjaro and Zepbound, so it has a commercial stake here. Still, patients shopping through Good Life's telehealth platform deserve support for those promises, especially the muscle-preservation pitch. The plus sign in Tirzepatide+ doesn't establish an added benefit. NAD also recommended changing ads that convey unsupported safety, efficacy, weight-loss, and personalization claims; keep that finding separate from a verdict on every compounded prescription.
Fierce Pharma, with Fraiser Kansteiner:
Beyond sales, which have been ticking up sequentially since Q2, patient volumes are moving back into positive territory, too. Following a “flat end to 2025” and a “slight decline” in Q1, Novo has subsequently added 1.2 million patients in the second quarter and now 1.2 million more in the third, which Doustdar called “quite encouraging.”
Novo's Wegovy pill brought in nearly $811 million in the third quarter, according to company results reported by Fierce Pharma. A pretty substantial tailwind—though Novo's overall sales growth was a more modest four percent at constant currencies. And Novo reports adding 1.2 million patients in Q3, after another 1.2 million in Q2. That's encouraging reach across obesity and diabetes; it still leaves me asking which insurance plans made room for those patients, and what they're paying to stay on treatment. Especially with Ozempic and injectable Wegovy still losing share to Lilly. Doustdar has a recovery case to make, and the pill gives him evidence—but those rosy 2027 launch expectations still have to become actual launches.
From Inderes:
The Phase 2b study is expected to enroll 150 participants, randomized 1:1:1 to CAM2056 10 mg, CAM2056 20 mg, or placebo, administered every four weeks following an initiation period. The primary objective is to demonstrate superiority of CAM2056 20 mg over placebo in reducing body weight after 36 weeks of treatment.
Camurus says its monthly semaglutide study has dosed its first patient. Fewer injections could be welcome—but with results expected in the first half of 2028, nobody should be planning a switch around this announcement. And the design matters: 150 participants, two CAM2056 doses and placebo, with weight loss measured at 36 weeks. No weekly semaglutide comparison arm—so this trial can't directly settle the company's suggestion that its monthly formulation could outperform weekly treatment. Every four weeks, after an initiation period. That could mean fewer injection days to organize your life around. But the dosing schedule alone tells us nothing about what a patient would pay. And 'faster and greater' weight loss is the CEO's description of the earlier, 80-person study. Company-reported promise; now higher doses get a longer test. I'm interested in the weight-loss numbers—and whether tolerability holds up.
Have feedback, a story idea, or a correction? Email us at glp1daily at lantern podcasts dot com. We’d love to hear what’s on your mind.
On the horizon: Novo Nordisk is targeting Wegovy pill launches in more than 20 countries by mid-2027, while Camurus anticipates results from its 150-participant LUNAR-2 trial of monthly semaglutide in the first half of 2028. Links to every story are in the show notes, so take a look at the ones you want to explore further. That's GLP-1 Daily for today. This is a Lantern Podcast.